Research on Complex Generics

Food and Drug Administration

Program description

The purpose of this funding opportunity is to expand access for Americans to high-quality, safe, and effective generic medicines, and help reduce the risk of drug shortages through a more competitive and multi-sourced generic drug market in the U.S., congruent with FDA’s Public Health Pillars.

Eligibility

Only the following applicant is eligible to apply for this single source funding: The University of Maryland

Past awards

Federal awards made under Assistance Listing 93.103 in FY2022–FY2026, from USAspending.gov.

Awards made
584
FY2022–FY2026
Total awarded
$537.9M
FY2022–FY2026
Typical award
$193K
Middle half $66.6K–$649.5K
States & territories
52
with at least one award

Typical award is the median of FY2026 awards; half of awards fell between the quartiles shown.

Awarded by fiscal year
YearTotal awardedAwards
FY2022
$109.8M
115
FY2023
$162.4M
172
FY2024
$123.4M
95
FY2025
$108.3M
128
FY2026
$33.9M
74

Where awards went

Top states by dollars, all years on record

  1. California$157.4M · 64 awards
  2. Arizona$156.6M · 21 awards
  3. Maryland$141.7M · 38 awards
  4. Pennsylvania$137.7M · 61 awards
  5. Virginia$125.2M · 32 awards

Who wins

Share of awards by recipient type

  • Unclassified by USAspending72% · 703 awards
  • Nonprofits10% · 97 awards
  • Colleges & universities10% · 95 awards
  • Small businesses4% · 40 awards
  • State & local governments4% · 36 awards
  • For-profit companies<1% · 7 awards

Source: USAspending.gov award records for this assistance listing, which can fund more than one opportunity. This is history, not a guarantee: future award sizes, counts and eligible recipients may differ. Exact total for FY2022–FY2026: $537,912,677.

Contact

Patrick Johnson Grants Management Specialist Food and Drug Administration

patrick.johnson@fda.hhs.gov